Neurodegenerative aspects of multiple system atrophy

Handbook of Neurotoxicity

Volumn 3, Issue , 2014, Pages 2157-2180

  Radford, Rowan ^a   Wong, Mathew ^a   Pountney, Dean L ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Aggresome; Alpha synuclein; Autophagy; Calcium; Chaperones; Metallothionein; Multiple system atrophy; Neuroinflammation; SUMO

Indexed keywords

EID: 84924237720     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5836-4_110     Document Type: Chapter

References (158)

1. Ahmed, Z., Asi, Y. T., Sailer, A., Lees, A. J., Houlden, H., Revesz, T., & Holton, J. L. (2012). The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathology and Applied Neurobiology, 38, 4-24.
2. Ahmed, Z., Asi, Y. T., Lees, A. J., Revesz, T., & Holton, J. L. (2013). Identification and quantification of oligodendrocyte precursor cells in multiple system atrophy progressive supranuclear palsy and Parkinson's disease. Brain Pathology, 23(3), 263-273. doi: 10.1111/ j.1750-3639.2012.00637.x.
3. Anderson, J. P., Walker, D. E., Goldstein, J. M., De Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J., Kling, K., Lee, M., Diep, L., Keim, P. S., Shen, X., Chataway, T., Schlossmacher, M. G., Seubert, P., Schenk, D., Sinha, S., Gai, W. P., & Chilcote, T. J. (2006). Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. The Journal of Biological Chemistry, 281, 29739-29752.
4. Aquilina, J. A., Benesch, J. L., Ding, L. L., Yaron, O., Horwitz, J., & Robinson, C. V. (2004). Phosphorylation of alphaB-crystallin alters chaperone function through loss of dimeric substructure. Journal of Biological Chemistry, 279, 28675-28680.
5. Arima, K., Murayama, S., Mukoyama, M., & Inose, T. (1992). Immunocytochemical and ultrastructural studies of neuronal and oligodendroglial cytoplasmic inclusions in multiple system atrophy. 1. Neuronal cytoplasmic inclusions. Acta Neuropathologica, 83, 453-460.
6. Berke, S. J., & Paulson, H. L. (2003). Protein aggregation and the ubiquitin proteasome pathway: Gaining the UPPer hand on neurodegeneration. Current Opinion in Genetics and Development, 13, 253-261.
7. Beyer, K., & Ariza, A. (2013). Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration. Molecular Neurobiology, 47, 509-524.
8. Bodner, R. A., Outeiro, T. F., Altmann, S., Maxwell, M. M., Cho, S. H., Hyman, B. T., McLean, P. J., Young, A. B., Housman, D. E., Kazantsev, A. G. (2006). Pharmacological promotion of inclusion formation: A therapeutic approach for Huntington's and Parkinson's diseases. Proceedings of the National Academy of Sciences USA, 103, 4246-4251.
9. Bolhuis, S., & Richter-Landsberg, C. (2010). Effect of proteasome inhibition by MG-132 on HSP27 oligomerization, phosphorylation, and aggresome formation in the OLN-93 oligodendroglia cell line. Journal of Neurochemistry, 114, 960-971.
10. Braithwaite, S. P., Stock, J. B., & Mouradian, M. M. (2012). a-Synuclein phosphorylation as a therapeutic target in Parkinson's disease. Reviews in Neuroscience, 23, 191-198.
11. Breydo, L., Wu, J. W., & Uversky, V. N. (2012). Alpha-synuclein misfolding and Parkinson's disease. Biochimica et Biophysica Acta, 1822, 261-285.
12. Bukhatwa, S., Zeng, B. Y., Rose, S., & Jenner, P. (2010). A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Brain Research, 1326, 174-183.
13. Cairns, N. J., Atkinson, P. F., Hanger, D. P., Anderton, B. H., Daniel, S. E., & Lantos, P. L. (1997). Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer's disease. Neuroscience Letters, 230, 49-52.
14. Carrasco, J., Adlard, P., Coman, D., Quintana, A., Penkowa, M., Xu, F., van Nostrand, W. E., & Hidalgo, J. (2006). Metallothionein-I and -III expression in animal models of Alzheimer's disease. Neuroscience, 143, 911-922.
15. Chin, L. S., Olzmann, J. A., & Li, L. (2010). Parkin-mediated ubiquitin signalling in aggresome formation and autophagy. Biochemical Society Transactions, 38, 144-149.
16. Chung, R. S., Hidalgo, J., & West, A. K. (2008). New insight into the molecular pathways of metallothionein-mediated neuroprotection and regeneration. Journal of Neurochemistry, 104, 14-20.
17. Conway, K. A., Lee, S. J., Rochet, J. C., Ding, T. T., Williamson, R. E., & Lansbury, P. T. Jr. (2000). Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proceedings of the National Academy of Sciences USA, 97, 571-576.
18. Cookson, M. R. (2009). a-Synuclein and neuronal cell death. Molecular Neurodegeneration, 4, 9.
19. Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., Hansen, L., Adame, A., Galasko, D., & Masliah, E. (2010). Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy. PLoS One, 5, e9313.
20. Danzer, K. M., Haasen, D., Karow, A. R., Moussaud, S., Habeck, M., Giese, A., Kretzschmar, H., Hengerer, B., & Kostka, M. (2007). Different species of a-synuclein oligomers induce calcium influx and seeding. Journal of Neuroscience, 27, 9220-9232.
21. Deleersnijder, A., Gerard, M., Debyser, Z., & Baekelandt, V. (2013). The remarkable conformational plasticity of alpha-synuclein: Blessing or curse? Trends in Molecular Medicine, 19, 368-377.
22. Drescher, M., van Rooijen, B. D., Veldhuis, G., Subramaniam, V., & Huber, M. (2010). A stable lipid-induced aggregate of alpha-synuclein. Journal of the American Chemical Society, 132, 4080-4082.
23. Eller, M., & Williams, D. R. (2011). a-Synuclein in Parkinson disease and other neurodegenerative disorders. Clinical Chemistry and Laboratory Medicine, 49, 403-408.
24. Feany, M. B., & Bender, W. W. (2000). A Drosophila model of Parkinson's disease. Nature, 404, 394-398.
25. Fellner, L., Jellinger, K. A., Wenning, G. K., & Stefanova, N. (2011). Glial dysfunction in the pathogenesis of a-synucleinopathies: Emerging concepts. Acta Neuropathologica, 121, 675-693.
26. Fellner, L., Irschick, R., Schanda, K., Reindl, M., Klimaschewski, L., Poewe, W., Wenning, G. K., & Stefanova, N. (2013). Toll-like receptor 4 is required for a-synuclein dependent activation of microglia and astroglia. Glia, 61, 349-360.
27. Fernagut, P. O., & Chesselet, M. F. (2004). Alpha-synuclein and transgenic mouse models. Neurobiology of Disease, 17, 123-130.
28. Fernagut, P. O., & Tison, F. (2012). Animal models of multiple system atrophy. Neuroscience, 211, 77-82.
29. Follett, J., Darlow, B., Wong, M. B., Goodwin, J., & Pountney, D. L. (2012). Potassium depolarization and raised calcium induces a-synuclein aggregates. Neurotoxicity Research, 23(4), 378-392.
30. Fredenburg, R. A., Rospigliosi, C., Meray, R. K., Kessler, J. C., Lashuel, H. A., Eliezer, D., & Lansbury, P. T., Jr. (2007). The impact of the E46K mutation on the properties of alpha- synuclein in its monomeric and oligomeric states. Biochemistry, 46, 7107-7118.
31. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002). Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nature Cell Biology, 4, 160-164.
32. Fusco, C., Micale, L., Egorov, M., Monti, M., D'addetta, E. V., Augello, B., Cozzolino, F., Calcagni, A., Fontana, A., Polishchuk, R. S., Didelot, G., Reymond, A., Pucci, P., & Merla, G. (2012). The E3-ubiquitin ligase TRIM50 interacts with HDAC6 and p62, and promotes the sequestration and clearance of ubiquitinated proteins into the aggresome. PLoS One, 7, e40440.
33. Gai, W. P., Power, J. H., Blumbergs, P. C., & Blessing, W. W. (1998). Multiple-system atrophy: A new alpha-synuclein disease? Lancet, 352(9127), 547-548.
34. Gai, W. P., Power, J. H., Blumbergs, P. C., Culvenor, J. G., & Jensen, P. H. (1999). Alpha- synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. Journal of Neurochemistry, 73, 2093-2100.
35. Gai, W. P., Pountney, D. L., Power, J. H. T., Blumbergs, P. C., Li, Q.-X., Culvenor, J. G., Jensen, P. H. (2003) Alpha-synuclein fibrils constitute the central core of oligodenroglial inclusion filaments in multiple system atrophy. Experimental Neurology, 181, 68-78.
36. Gilman, S., Wenning, G. K., Low, P. A., Brooks, D. J., Mathias, C. J., Trojanowski, J. Q., Wood, N. W., Colosimo, C., Durr, A., Fowler, C. J., Kaufmann, H., Klockgether, T., Lees, A., Poewe, W., Quinn, N., Revesz, T., Robertson, D., Sandroni, P., Seppi, K., & Vidailhet, M. (2008). Second consensus statement on the diagnosis of multiple system atrophy. Neurology, 71, 670-676.
37. Gomez-Tortosa, E., Gonzalo, I., Newell, K., Garcia Yebenes, J., Vonsattel, P., & Hyman, B. T. (2002). Patterns of protein nitration in dementia with Lewy bodies and striatonigral degeneration. Acta Neuropathologica, 103, 495-500.
38. Goodwin, J., Nath, S., Engelborghs, Y., & Pountney, D. L. (2012). Raised calcium and oxidative stress cooperatively promote alpha-synuclein aggregate formation. Neurochemistry International, 62(5), 703-711. doi:pii:%20S0197-0186(12)00356-7.%2010.1016/j.neuint.2012.11.004.
39. Graham, J. G., & Oppenheimer, D. R. (1969). Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. Journal of Neurology, Neurosurgery, and Psychiatry, 32, 28-34.
40. Hasegawa, T., Baba, T., Kobayashi, M., Konno, M., Sugeno, N., Kikuchi, A., Itoyama, Y., & Takeda, A. (2010). Role of TPPP/p25 on a-synuclein-mediated oligodendroglial degeneration and the protective effect of SIRT2 inhibition in a cellular model of multiple system atrophy. Neurochemistry International, 57, 857-866.
41. 2+ signaling in human neuroblastoma (SH-SY5Y) cells. Journal of Neurochemistry, 111, 1192-1201.
42. Huang, Y., Song, Y. J., Murphy, K., Holton, J. L., Lashley, T., Revesz, T., Gai, W. P., & Halliday, G. M. (2008). LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Acta Neuropathologica, 116, 639-646.
43. Ishizawa, K., Komori, T., Sasaki, S., Arai, N., Mizutani, T., & Hirose, T. J. (2004). Microglial activation parallels system degeneration in multiple system atrophy. Journal of Neuropathology and Experimental Neurology, 63, 43-52.
44. Ishizawa, K., Komori, T., Arai, N., Mizutani, T., & Hirose, T. (2008). Glial cytoplasmic inclusions and tissue injury in multiple system atrophy: A quantitative study in white matter (olivopontocerebellar system) and gray matter (nigrostriatal system). Neuropathology, 28, 249-257.
45. Iwata, A., Riley, B. E., Johnston, J. A., & Kopito, R. R. (2005). HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. The Journal of Biological Chemistry, 280, 40282-40292.
46. Jellinger, K. A. (2003). Neuropathological spectrum of synucleinopathies. Movement Disorders: Official Journal of the Movement Disorder Society, 18(Suppl 6), S2-S12.
47. Jellinger, K. A., & Lantos, P. L. (2010). Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: An update. Acta Neuropathologica, 119, 657-667.
48. Johnston, J. A., Ward, C. L., & Kopito, R. R. (1998). Aggresomes: A cellular response to misfolded proteins. The Journal of Cell Biology, 143, 1883-1898.
49. Jomova, K., Vondrakova, D., Lawson, M., & Valko, M. (2010). Metals, oxidative stress and neurodegenerative disorders. Molecular and Cellular Biochemistry, 345, 91-104.
50. Ju, J. A., Miller, S. E., Hanson, P. I., & Weihl, C. C. (2008). Impaired protein aggregate handling and clearance underlie the pathogenesis of p97/VCP-associated disease. The Journal of Biological Chemistry, 283, 30289-30299.
51. Kaushik, S., Bandyopadhyay, U., Sridhar, S., Kiffin, R., Martinez-Vicente, M., Kon, M., Orenstein, S. J., Wong, E., & Cuervo, A. M. (2011). Chaperone-mediated autophagy at a glance. Journal of Cell Science, 124, 495-499.
52. Kawamoto, Y., Nakamura, S., Akiguchi, I., & Kimura, J. (1999). Increased brain-derived neurotrophic factor-containing axons in the basal ganglia of patients with multiple system atrophy. Journal of Neuropathology and Experimental Neurology, 58, 765-772.
53. Kawamoto, Y., Nakamura, S., Matsuo, A., & Akiguchi, I. (2000). Glial cell line-derived neurotrophic factor-like immunoreactivity in the cerebella of normal subjects and patients with multiple system atrophy. Acta Neuropathologica, 100, 131-137.
54. Kawamoto, Y., Akiguchi, I., Shirakashi, Y., Honjo, Y., Tomimoto, H., Takahashi, R., & Budka, H. (2007). Accumulation of Hsc70 and Hsp70 in glial cytoplasmic inclusions in patients with multiple system atrophy. Brain Research, 1136, 219-227.
55. Kiely, A. P., Asi, Y. T., Kara, E., Limousin, P., Ling, H., Lewis, P., Proukakis, C., Quinn, N., Lees, A. J., Hardy, J., Revesz, T., Houlden, H., & Holton, J. L. (2013). a-synucleinopathy associated with G51D SNCA mutation: A link between Parkinson's disease and multiple system atrophy? Acta Neuropathologica, 125, 753-769.
56. Kikuchi, A., Takeda, A., Onodera, H., Kimpara, T., Hisanaga, K., Sato, N., Nunomura, A., Castellani, R. J., Perry, G., Smith, M. A., & Itoyama, Y. (2002). Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiology of Disease, 9, 244-248.
57. Klionsky, D. J., Baehrecke, E. H., Brumell, J. H., Chu, C. T., Codogno, P., Cuervo, A. M., Debnath, J., Deretic, V., Elazar, Z., Eskelinen, E. L., Finkbeiner, S., Fueyo-Margareto, J., Gewirtz, D., Jaattela, M., Kroemer, G., Levine, B., Melia, T. J., Mizushima, N., Rubinsztein, D. C., Simonsen, A., Thorburn, A., Thumm, M., & Tooze, S. A. (2011). Autophagy, 7, 1273-1294.
58. Konno, M., Hasegawa, T., Baba, T., Miura, E., Sugeno, N., Kikuchi, A., Fiesel, F. C., Sasaki, T., Aoki, M., Itoyama, Y., & Takeda, A. (2012). Suppression of dynamin GTPase decreases alpha- synuclein uptake by neuronal and oligodendroglial cells: A potent therapeutic target for synucleinopathy. Molecular Neurodegeneration, 71, 38.
59. Kopito, R. R. (2000). Aggresomes, inclusion bodies and protein aggregation. Trends in Cell Biology, 10, 524-530.
60. Kostenko, S., & Moens, U. (2009). Heat shock protein 27 phosphorylation: Kinases, phosphatases, functions and pathology. Cellular and Molecular Life Science, 66, 3289-3307.
61. Kragh, C. L., Lund, L. B., Febbraro, F., Hansen, H. D., Gai, W. P., El-Agnaf, O., Richter-Landsberg, C., & Jensen, P. H. (2009). Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. The Journal of Biological Chemistry, 284, 10211-10222.
62. Kragh, C. L., Fillon, G., Gysbers, A., Hansen, H. D., Neumann, M., Richter-Landsberg, C., Haass, C., Zalc, B., Lubetzki, C., Gai, W. P., Halliday, G. M., Kahle, P. J., & Jensen, P. H. (2013). FAS-dependent cell death in a-synuclein transgenic oligodendrocyte models of multiple system atrophy. PLoS One, 8(1), e55243.
63. Krumova, P., Meulmeester, E., Garrido, M., Tirard, M., Hsiao, H. H., Bossis, G., Urlaub, H., Zweckstetter, M., Kiigler, S., Melchior, F., Bahr, M., & Weishaupt, J. H. (2011). Sumoylation inhibits alpha-synuclein aggregation and toxicity. Journal of Cell Biology, 194, 49-60.
64. Krumova, P., Weishaupt, J.H. (2012). Sumoylation in neurodegenerative diseases. Cellular and Molecular Life Sciences, 70, 2123-2138.
65. Kulathu, Y., & Komander, D. (2012). Atypical ubiquitylation - The unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nature Reviews. Molecular Cell Biology, 13, 508-523.
66. Lavedan, C. (1998). The synuclein family. Genome Research, 8, 871-880.
67. Lee, J. A. (2009). Autophagy in neurodegeneration: Two sides of the same coin. BMB Report, 42, 324-330.
68. Lee, S. J., & Koh, J. Y. (2010). Roles of zinc and metallothionein-3 in oxidative stress-induced lysosomal dysfunction, cell death, and autophagy in neurons and astrocytes. Molecular Brain, 3(1), 30.
69. Lee, S. J., Cho, K. S., Kim, H. N., Kim, H. J., & Koh, J. Y. (2011). Role of zinc metallothionein-3 (ZnMt3) in epidermal growth factor (EGF)-induced c-Abl protein activation and actin polymerization in cultured astrocytes. The Journal of Biological Chemistry, 286, 40847-40856.
70. Leong, S. L., Cappai, R., Barnham, K. J., & Pham, C. L. (2009). Modulation of alpha-synuclein aggregation by dopamine: A review. Neurochemistry Research, 34, 1838-1846.
71. Lesage, S., & Brice, A. (2009). Parkinson's disease: From monogenic forms to genetic susceptibility factors. Human Molecular Genetics, 18(R1), R48-R59.
72. Lindersson, E., Beedholm, R., Højrup, P., Moos, T., Gai, W., Hendil, K. B., & Jensen, P. H. (2004). Proteasomal inhibition by alpha-synuclein filaments and oligomers. The Journal of Biological Chemistry, 279, 12924-12934.
73. Lindersson, E., Lundvig, D., Petersen, C., Madsen, P., Nyengaard, J. R., Højrup, P., Moos, T., Otzen, D., Gai, W. P., Blumbergs, P. C., & Jensen, P. H. (2005). p25alpha stimulates alpha- synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synuclei- nopathies. The Journal of Biological Chemistry, 280, 5703-5715.
74. Lowe, R., Pountney, D. L., Jensen, P. H., Gai, W. P., & Voelcker, N. H. (2004). Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Science, 13, 3245-3252.
75. Manso, Y., Adlard, P. A., Carrasco, J., Vasak, M., & Hidalgo, J. (2011). Metallothionein and brain inflammation. Journal of Biological Inorganic Chemistry, 16, 1103-1113.
76. Marpillat, N. (2013). Prevalence of rare diseases: Bibliographic data, Orphanet Report Series, http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence:of_rare_diseases_by_alphabe- tical_list.pdf.
77. Marques, O., & Outeiro, T. F. (2012). Alpha-synuclein: From secretion to dysfunction and death. Cell Death and Disease, 3, e350. doi:"10.1038".
78. Martin, S., Wilkinson, K. A., Nishimune, A., & Henley, J. M. (2007). Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction. Nature Reviews. Neuroscience, 8, 948-959.
79. Mattson, M. P. (2007). Calcium and neurodegeneration. Aging Cell, 6, 337-350.
80. Miller, D. W., Johnson, J. M., Solano, S. M., Hollingsworth, Z. R., Standaert, D. G., & Young, A. B. (2005). Absence of alpha-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. Journal of Neural Transmission, 112, 1613-1624.
81. Mosharov, E. V., Larsen, K. E., Kanter, E., Phillips, K. A., Wilson, K., Schmitz, Y., Krantz, D. E., Kobayashi, K., Edwards, R. H., & Sulzer, D. (2009). Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron, 62, 218-229.
82. Muchowski, P. J., & Wacker, J. L. (2005). Modulation of neurodegeneration by molecular chaperones. Nature Reviews in Neuroscience, 6, 11-22.
83. Nath, S., Goodwin, J., Engelborghs, Y., & Pountney, D. L. (2011). Raised calcium promotes a-synuclein aggregate formation. Molecular and Cellular Neuroscience, 46, 516-526.
84. Nemani, V. M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M. K., Chaudhry, F. A., Nicoll, R. A., & Edwards, R. H. (2010). Increased expression of a-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron, 65, 66-79.
85. 2+ binding to a-synuclein regulates ligand binding and oligomerization. The Journal of Biological Chemistry, 276, 22680-22684.
86. Nishie, M., Mori, F., Yoshimoto, M., Takahashi, H., & Wakabayashi, K. (2004). A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy. Neuropathology and Applied Neurobiology, 30, 546-554.
87. Norris, E. H., & Giasson, B. I. (2005). Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders. Antioxidants and Redox Signalling, 7, 672-684.
88. Olzmann, J. A., Li, L., Chudaev, M. V., Chen, J., Perez, F. A., Palmiter, R. D., & Chin, L. S. (2007). Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. The Journal of Cell Biology, 178, 1025-1038.
89. Olzmann, J. A., Li, L., & Chin, L. S. (2008). Aggresome formation and neurodegenerative diseases: Therapeutic implications. Current Medicinal Chemistry, 15, 47-60.
90. Ouyang, H., Ali, Y. O., Ravichandran, M., Dong, A., Qiu, W., Mackenzie, F., Dhe-Paganon, S., Arrowsmith, C. H., & Zhai, R. G. (2012). Protein aggregates are recruited to aggresome by histone deacetylase 6 via unanchored ubiquitin C termini. The Journal ofBiological Chemistry, 287, 2317-2327.
91. Ozawa, T. (2006). Pathology and genetics of multiple system atrophy: an approach to determining genetic susceptibility spectrum. Acta Neuropathologica, 112, 531-538.
92. Ozawa, T., Paviour, D., Quinn, N. P., Josephs, K. A., Sangha, H., Kilford, L., Healy, D. G., Wood, N. W., Lees, A. J., Holton, J. L., & Revesz, T. (2004). The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: Clinicopathological correlations. Brain, 127, 2657-2671.
93. Papp, M. I., & Lantos, P. L. (1994). The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain, 117, 235-243.
94. Papp, M. I., Kahn, J. E., & Lantos, P. L. (1989). Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). Journal of Neurological Sciences, 94(1-3), 79-100.
95. Pellecchia, M. T., Pivonello, R., Longo, K., Manfredi, M., Tessitore, A., Amboni, M., Pivonello, C., Rocco, M., Cozzolino, A., Colao, A., & Barone, P. (2010). Multiple system atrophy is associated with changes in peripheral insulin-like growth factor system. Movement Disorders: Official Journal of the Movement Disorder Society, 25, 2621-2626.
96. Perlmutter, J. D., Braun, A. R., & Sachs, J. N. (2009). Curvature dynamics of alpha-synuclein familial Parkinson disease mutants: Molecular simulations of the micelle- and bilayer-bound forms. Journal of Biological Chemistry, 284, 7177-7189.
97. Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., Stenroos, E. S., Chandrasekharappa, S., Athanassiadou, A., Papapetropoulos, T., Johnson, W. G., Lazzarini, A. M., Duvoisin, R. C., Di Iorio, G., Golbe, L. I., & Nussbaum, R. L. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
98. Pountney, D. L., Huang, Y., Burns, R. J., Haan, E., Thompson, P. D., Blumbergs, P. C., & Gai, W. P. (2003). SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease. Experimental Neurology, 184, 436-446.
99. Pountney, D. L., Lowe, R., Quilty, M., Vickers, J. C., Voelcker, N. H., & Gai, W. P. (2004). Annular alpha-synuclein species from purified multiple system atrophy inclusions. Journal of Neurochemistry, 90, 502-512.
100. Pountney, D. L., Voelcker, N. H., & Gai, W. P. (2005a). Annular a-synuclein oligomers are potentially toxic agents in a-synucleinopathy. Neurotoxicity Research, 7, 59-67.
101. Pountney, D. L., Treweek, T. M., Chataway, T., Huang, Y., Chegini, F., Blumbergs, P. C., Raftery, M. J., & Gai, W. P. (2005b). Alpha B-crystallin is a major component of glial cytoplasmic inclusions in multiple system atrophy. Neurotoxicity Research, 7(1-2), 77-85.
102. Pountney, D. L., Chegini, F., Shen, X., Blumbergs, P. C., & Gai, W. P. (2005c). SUMO-1 marks subdomains within glial cytoplasmic inclusions of multiple system atrophy. Neuroscience Letters, 381, 74-79.
103. Pountney, D. L., Raftery, M. J., Chegini, F., Blumbergs, P. C., & Gai, W. P. (2008). NSF, Unc-18-1, dynamin-1 and HSP90 are inclusion body components in neuronal intranuclear inclusion disease identified by anti-SUMO-1-immunocapture. Acta Neuropathologica, 116, 603-614.
104. Pountney, D. L., Dickson, T. C., Power, J. H., Vickers, J. C., West, A. K., & Gai, W. P. (2011). Association of metallothionein-III with oligodendroglial cytoplasmic inclusions in multiple system atrophy. Neurotoxicity Research, 19, 115-122.
105. Putcha, P., Danzer, K. M., Kranich, L. R., Scott, A., Silinski, M., Mabbett, S., Hicks, C. D., Veal, J. M., Steed, P. M., Hyman, B. T., & Mclean, P. J. (2010). Brain-permeable small-molecule inhibitors of Hsp90 prevent a-synuclein oligomer formation and rescue a-synuclein-induced toxicity. The Journal of Pharmacology and Experimental Therapeutics, 332, 849-857.
106. Qing, H., Wong, W., McGeer, E. G., & McGeer, P. L. (2009). Lrrk2 Phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochemical Biophysical Research Communications, 387, 149-152.
107. Radford, R., Guillemin, G., & Pountney, D. L. (unpublished data).
108. Rami, A. (2009). Review: Autophagy in neurodegeneration: Firefighter and/or incendiarist? Neuropathology and Applied Neurobiology, 35, 449-461.
109. Rekas, A., Adda, C. G., Aquilina, J. A., Barnham, K. J., Sunde, M., Galatis, D., Williamson, N. A., Masters, C. L., Anders, R. F., Robinson, C. V., Cappai, R., & Carver, J. A. (2004). Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: Effects on amyloid fibril formation and chaperone activity. Journal of Molecular Biology, 340, 1167-1183.
110. Richter-Landsberg, C., Gorath, M., Trojanowski, J. Q., & Lee, V. M. (2000). a-synuclein is developmentally expressed in cultured rat brain oligodendrocytes. Journal of Neuroscience Research, 62, 9-14.
111. Rott, R., Szargel, R., Haskin, J., Bandopadhyay, R., Lees, A. J., Shani, V., & Engelender, S. (2011). a-Synuclein fate is determined by USP9X-regulated monoubiquitination. Proceedings of the National Academy of Sciences of the United States of America, 108, 18666-18671.
112. Ruiperez, V., Darios, F., & Davletov, B. (2010). Alpha-synuclein, lipids and Parkinson's disease. Progress in Lipid Research, 49, 420-428.
113. Sahu, R., Kaushik, S., Clement, C. C., Cannizzo, E. S., Scharf, B., Follenzi, A., Potolicchio, I., Nieves, E., Cuervo, A. M., & Santambrogio, L. (2011). Microautophagy of cytosolic proteins by late endosomes. Developmental Cell, 20, 131-139.
114. Schildknecht, S., Gerding, H. R., Karreman, C., Drescher, M., Lashuel, H. A., Outeiro, T. F., Di Monte, D. A., & Leist, M. (2013). Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: Implications for disease mechanisms and interventions in synuclei- nopathies. Journal of Neurochemistry, 125, 491-511.
115. Schmidt, F., Levin, J., Kamp, F., Kretzschmar, H., Giese, A., & Botzel, K. (2012). Single-channel electrophysiology reveals a distinct and uniform pore complex formed by a-synuclein oligomers in lipid membranes. PLoS One, 7(8), e42545.
116. Schrag, A., Ben-Shlomo, Y., & Quinn, N. P. (1999). Prevalence of progressive supranuclear palsy and multiple system atrophy: A cross-sectional study. Lancet, 354, 1771-1775.
117. Schwarz, L., Goldbaum, O., Bergmann, M., Probst-Cousin, S., & Richter-Landsberg, C. (2012). Involvement of macroautophagy in multiple system atrophy and protein aggregate formation in oligodendrocytes. Journal of Molecular Neuroscience, 47, 256-266.
118. Shibata, N., Inose, Y., Toi, S., Hiroi, A., Yamamoto, T., & Kobayashi, M. (2010). Involvement of 4-hydroxy-2-nonenal accumulation in multiple system atrophy. Acta Histochemica Cytochemica, 43, 69-75.
119. Shimura, H., Schlossmacher, M. G., Hattori, N., Frosch, M. P., Trockenbacher, A., Schneider, R., Mizuno, Y., Kosik, K. S., & Selkoe, D. J. (2001). Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease. Science, 293, 263-269.
120. Snyder, H., Mensah, K., Theisler, C., Lee, J., Matouschek, A., & Wolozin, B. (2003). Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. The Journal of Biological Chemistry, 278, 11753-11759.
121. Sofroniew, M. V. (2009). Molecular dissection of reactive astrogliosis and glial scar formation. Trends in Neurosciences, 32, 638-647.
122. Song, Y. J., Lundvig, D. M., Huang, Y., Gai, W. P., Blumbergs, P. C., Højrup, P., Otzen, D., Halliday, G. M., & Jensen, P. H. (2007). p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. The American Journal of Pathology, 171, 1291-1303.
123. Song, Y. J., Halliday, G. M., Holton, J. L., Lashley, T., O'Sullivan, S. S., McCann, H., Lees, A. J., Ozawa, T., Williams, D. R., Lockhart, P. J., & Revesz, T. R. (2009). Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. Journal of Neuropathology and Experimental Neurology, 68, 1073-1083.
124. Spillantini, M. G., & Goedert, M. (2000). The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Annals of the New York Academy of Sciences, 920, 16-27.
125. Stefanova, N., Reindl, M., Neumann, M., Haass, C., Poewe, W., Kahle, P. J., & Wenning, G. K. (2005). Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. The American Journal of Pathology, 166, 869-876.
126. Stefanova, N., Reindl, M., Neumann, M., Kahle, P. J., Poewe, W., & Wenning, G. K. (2007). Microglial activation mediates neurodegeneration related to oligodendroglial alpha- synucleinopathy: Implications for multiple system atrophy. Movement Disorders, 22, 2196-2203.
127. Stefanova, N., Bucke, P., Duerr, S., & Wenning, G. K. (2009). Multiple system atrophy: An update. Lancet Neurology, 8, 1172-1178.
128. Stefanova, N., Kaufmann, W. A., Humpel, C., Poewe, W., & Wenning, G. K. (2012). Systemic proteasome inhibition triggers neurodegeneration in a transgenic mouse model expressing human a-synuclein under oligodendrocyte promoter: Implications for multiple system atrophy. Acta Neuropathologica, 124, 51-65.
129. Stemberger, S., Scholz, S. W., Singleton, A. B., & Wenning, G. K. (2011) Genetic players in multiple system atrophy: Unfolding the nature of the beast. Neurobiology of Aging, 32, 1924.e5-14.
130. Su, M., Yoshida, Y., Hirata, Y., Watahiki, Y., & Nagata, K. (2001). Primary involvement of the motor area in association with the nigrostriatal pathway in multiple system atrophy: Neuropathological and morphometric evaluations. Acta Neuropathologica, 101, 57-64.
131. Su, W. H., Lukiw, W. J., Bergeron, C., Niznik, H. B., & Fraser, P. E. (2001). Metallothionein III is reduced in Alzheimer's disease. Brain Research, 894, 37-45.
132. Suntharalingam, A., Abisambra, J. F., O'leary, J. C., 3rd, Koren, J., 3rd, Zhang, B., Joe, M. K., Blair, L. J., Hill, S. E., Jinwal, U. K., Cockman, M., Duerfeldt, A. S., Tomarev, S., Blagg, B. S., Lieberman, R. L., & Dickey, C. A. (2012). Grp94 triage of mutant myocilin through ERAD subverts a more efficient autophagic clearance mechanism. The Journal of Biological Chemistry, 287(48), 40661-40669.
133. Sulzer, D. (2010). Clues to how alpha-synuclein damages neurons in Parkinson's disease. Movement Disorders, 25(Suppl 1), S27-S31.
134. Taylor, J. P., Tanaka, F., Robitschek, J., Sandoval, C. M., Taye, A., Markovic-Plese, S., & Fischbeck, K. H. (2003). Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Human Molecular Genetics, 12, 749-757.
135. Taylor, J. M., Brody, K. M., & Lockhart, P. J. (2012). Parkin Co-Regulated Gene is involved in aggresome formation and autophagy in response to proteasomal impairment. Experimental Cell Research, 318, 2059-2070.
136. Thomas, M., Harrell, J. M., Morishima, Y., Peng, H. M., Pratt, W. B., & Lieberman, A. P. (2006). Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction. Human Molecular Genetics, 15, 1876-1883.
137. Trempe, J. F. (2011). Reading the ubiquitin postal code. Current Opinion in Structural Biology, 21, 792-801.
138. Tsuji, S., & Members of the Multiple-System Atrophy Research Collaboration. (2013). Mutations in COQ2 in familial and sporadic multiple-system atrophy. New England Journal of Medicine. doi:10.1056/NEJMoa1212115.
139. Ubhi, K., Lee, P. H., Adame, A., Inglis, C., Mante, M., Rockenstein, E., Stefanova, N., Wenning, G. K., & Masliah, E. (2009). Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. Journal of Neuroscience Research, 87, 2728-2739.
140. Uchida, Y., Takio, K., Titani, K., Ihara, Y., & Tomonaga, M. (1991). The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron, 7, 337-347.
141. Uryu, K., Richter-Landsberg, C., Welch, W., Sun, E., Goldbaum, O., Norris, E. H., Pham, C. T., Yazawa, I., Hilburger, K., Micsenyi, M., Giasson, B. I., Bonini, N. M., Lee, V. M., & Trojanowski, J. Q. (2006). Convergence of heat shock protein 90 with ubiquitin in filamentous alpha-synuclein inclusions of alpha-synucleinopathies. The American Journal of Pathology, 168, 947-961.
142. Uversky, V. N. (2009). Intrinsic disorder in proteins associated with neurodegenerative diseases. Frontiers in Bioscience, 14, 5188-5238.
143. Uversky, V. N., & Eliezer, D. (2009). Biophysics of Parkinson's disease: Structure and aggregation of a-synuclein. Current Protein and Peptide Science, 10, 483-499.
144. Vasak, M. (2005). Advances in metallothionein structure and functions. Journal of Trace Elements in Medicine and Biology, 19, 13-17.
145. Vekrellis, K., & Stefanis, L. (2012). Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies. Expert Opinion on Therapeutic Targets, 16, 421-432.
146. Verkhratsky, A., Sofroniew, M. V., Messing, A., Delanerolle, N. C., Rempe, D., Rodriguez, J. J., & Nedergaard, M. (2012). Neurological diseases as primary gliopathies: A reassessment of neurocentrism. ASNNeuro, 4(3), 131-149. doi:"10.1042/AN20120010".
147. Vilar, M., Chou, H. T., Lührs, T., Maji, S. K., Riek-Loher, D., Verel, R., Manning, G., Stahlberg, H., & Riek, R. (2008) The fold of alpha-synuclein fibrils. Proceedings of the National Academy of Sciences USA, 105, 8637-8642.
148. Vilarmo-Giiell, C., Soto-Ortolaza, A. I., Rajput, A., Mash, D. C., Papapetropoulos, S., Pahwa, R., Lyons, K. E., Uitti, R. J., Wszolek, Z. K., Dickson, D. W., Farrer, M. J., & Ross, O. A. (2011). MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology, 76, 670-672.
149. Waudby, C. A., Knowles, T. P., Devlin, G. L., Skepper, J. N., Ecroyd, H., Carver, J. A., Welland, M. E., Christodoulou, J., Dobson, C. M., & Meehan, S. (2010). The interaction of alphaB- crystallin with mature alpha-synuclein amyloid fibrils inhibits their elongation. Biophysical Journal, 98, 843-851.
150. Wenning, G. K., & Jellinger, K. A. (2005). The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathologica, 109, 129-140.
151. Wenning, G. K., & Stefanova, N. (2009). Recent developments in multiple system atrophy. Journal of Neurology, 256, 1791-1808.
152. Wenning, G. K., Tison, F., Ben Shlomo, Y., Daniel, S. E., & Quinn, N. P. (1997). Multiple system atrophy: A review of 203 pathologically proven cases. Movement Disorders: Official Journal of the Movement Disorder Society, 12, 133-147.
153. Wenning, G. K., Colosimo, C., Geser, F., & Poewe, W. (2004). Multiple system atrophy. Lancet Neurology, 3, 93-103.
154. Wenning, G. K., Stefanova, N., Jellinger, K. A., Poewe, W., & Schlossmacher, M. G. (2008). Multiple system atrophy: A primary oligodendrogliopathy. Annals of Neurology, 64, 239-246.
155. West, A. K., Hidalgo, J., Eddins, D., Levin, E. D., & Aschner, M. (2008). Metallothionein in the central nervous system: Roles in protection, regeneration and cognition. NeuroToxicology, 29, 489-503.
156. Wong, E., & Cuervo, A. M. (2010). Autophagy gone awry in neurodegenerative diseases. Nature Neuroscience, 13, 805-811.
157. Wong, M. B., Goodwin, J., Norazit, A., Meedeniya, A. C. B., Richter-Landsberg, C., Gai, W. P., & Pountney, D. L. (2013). SUMO-1 is associated with a subset of lysosomes in glial protein aggregate diseases. Neurotoxicity Research, 23, 1-21.
158. Yamada, T., McGeer, P. L., Baimbridge, K. G., & McGeer, E. G. (1990). Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Research, 526, 303-307.